SeaCrest Wealth Management’s Myriad Genetics MYGN Stock Holding History

SeaCrest Wealth Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-14,675	Closed	-$191K	–	638
2020 Q3	$191K	Buy	+14,675	New	+$186K	0.03%	523
2019 Q2	–	Sell	-650	Closed	-$22K	–	1348
2019 Q1	$22K	Buy	650 +350	+117%	+$10.7K	﹤0.01%	1247
2018 Q4	$9K	Hold	300	–	–	﹤0.01%	1529
2018 Q3	$14K	Hold	300	–	–	﹤0.01%	1516
2018 Q2	$11K	Hold	300	–	–	﹤0.01%	1580
2018 Q1	$9K	Hold	300	–	–	﹤0.01%	1623
2017 Q4	$10K	Buy	+300	New	+$10.1K	﹤0.01%	1597

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SeaCrest Wealth Management's MYGN Position: Q4 2020 in Review

SeaCrest Wealth Management sold out of Myriad Genetics (MYGN) in Q4 2020, closing a stake of 14,675 shares — an estimated $191K sold.

SeaCrest Wealth Management first reported a position in MYGN in Q4 2017 and held it in 7 quarters. The position peaked at $191K in Q3 2020. 187 funds tracked by Wall St. Rank hold MYGN as of Q4 2020.

SeaCrest Wealth Management reported no remaining Myriad Genetics position as of Q4 2020 after selling out during the quarter.
SeaCrest Wealth Management sold 14,675 Myriad Genetics shares in Q4 2020, an estimated $191K.
SeaCrest Wealth Management first reported a position in Myriad Genetics in Q4 2017 and held it in 7 quarters.
SeaCrest Wealth Management's Myriad Genetics position peaked at $191K in Q3 2020.
187 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2020.

Based on SeaCrest Wealth Management's 13F filing for Q4 2020, filed 9 Feb 2021.